Impact Analysis of Covid-19
The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
Global Premature Ejaculation Treatment Market, by Drug Type (Selective Serotonin Reuptake Inhibitors (SSRIs) (Dapoxetine, and Others), Phosphodiesterase Type 5 (PDE5) Inhibitors (Zertane, and Others), Topical Anesthetics, and Others), by Route of Administration (Oral and Topical), by Dosage Form (Pills, Spray, and Others), by Distribution Channel (Hospitals, Online Pharmacies, and Retail Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa) was valued at US$ 1.5 Bn in 2017 and is estimated to exhibit a CAGR of 8.7% over the forecast period (2018-2026).
Get FREE Sample PDF Including COVID-19 Impact Analysis: https://www.coherentmarketinsights.com/insight/request-pdf/1956
The global premature ejaculation treatment market is expected to witness significant growth over the forecast period, attributed to increasing number of product launches by key players and robust pipeline of novel products for treatment of premature ejaculation. Furthermore, rising prevalence of premature ejaculation among people, owing to unhealthy lifestyle is further expected to drive demand for its treatment products and thereby expected to fuel the market growth over the forecast period. For instance, in 2016, Regent Pacific Group Limited, a Hong Kong-based investment group launched its product Fortacin in the U.K. Fortacin is a topical spray, which contains low doses of two anesthetics – lidocaine and prilocaine and is indicated for the treatment of premature ejaculation. Similarly, in 2013, Menarini Group, an Italy-based pharmaceutical company launched Priligy (dapoxetine) in Singapore, that is indicated for the treatment of premature ejaculation. Priligy (dapoxetine) rapidly increases synaptic levels of serotonin in the central nervous system, thus improving symptoms of PE.
Browse 37 Market Data Tables and 40 Figures spread through 198 Pages and in-depth TOC on Premature Ejaculation Treatment Market by Drug Type (Selective Serotonin Reuptake Inhibitors (SSRIs) (Dapoxetine, and Others), Phosphodiesterase Type 5 (PDE5) Inhibitors (Zertane, and Others), Topical Anesthetics, and Others), by Route of Administration (Oral and Topical), by Dosage Form (Pills, Spray, and Others), by Distribution Channel (Hospitals, Online Pharmacies, and Retail Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa) – Global Forecast to 2026
To know the latest trends and insights prevalent in the Premature Ejaculation Treatment Market Press Release, click the link below: https://bit.ly/33xARU9
Additionally, market players in the market are focusing on adopting growth strategies such as mergers and acquisitions, partnerships, and collaborations, in order to launch new drugs indicated for the treatment of premature ejaculation. This is expected to aid in gaining a strong foothold in the market and also creates a lucrative opportunity for other key players to focus on and provide novel drugs for premature ejaculation treatment. For instance, in 2012, Furiex Pharmaceuticals, Inc. and Menarini Group entered into strategic partnership and signed a license agreement. According to the agreement, Furiex Pharmaceuticals, Inc. licensed Menarini rights to commercialize Priligy in Europe, most of Asia, Africa, Latin America, and Middle East.
Furthermore, rising prevalence of premature ejaculation is expected to augment demand for premature treatment products over the forecast period. For instance, according to the data published by Arab Journal of Urology 2013, globally premature ejaculation affects up to 30% of men of all age group. Thus, such high prevalence of premature ejaculation is expected to significantly increase demand for its treatment drug and further expected to drive the global premature ejaculation treatment market growth, over the forecast period.
Key Takeaways of the Premature Ejaculation Treatment Market:
- The global premature ejaculation treatment market is expected to exhibit a CAGR of 8.7% over the forecast period (2018-2026), attributed to increasing number of product launches, regulatory product approvals, and increasing research and development activities by key players for development of novel products
- Among regions, North America is expected to hold the dominant position in the global premature ejaculation treatment market over the forecast period (2018 – 2026). This is attributed to increasing prevalence of premature ejaculation in the region. For instance, according to the American Urological Association (AUA), in U.S premature ejaculation is the most common form of male sexual dysfunction, affecting about 1 in three 3 aged 18 to 59.
- Moreover, Asia Pacific is expected to witness significant growth over the forecast period, attributed to increasing launches of novel premature ejaculation treatment drug by key players in the region. For instance, in 2013, Menarini Group, an Italy-based pharmaceutical company, launched its Priligy (dapoxetine) in Singapore.
- Key players operating in the premature ejaculation treatment market include Regent Pacific Group Limited, Menarini Group, Furiex Pharmaceuticals, Inc., Absorption Pharmaceuticals, LLC, Ampio Pharmaceuticals, Inc., Aytu BioScience, NeuroHealing Pharmaceuticals Inc., and Dong-A Pharmaceutical Co., Ltd.
Apply Promo Code “STAYHOME” And Get Instant Discount Of USD 1000
Buy Now this Premium Report to Grow your Business @ https://www.coherentmarketinsights.com/insight/buy-now/1956
About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837
